Bipolar androgen therapy (BAT), as a new therapeutic strategy for castration-resistant prostate cancer (CRPC), can significantly reduce the level of prostate-specific antigen (PSA) for prostate cancer patients and has exhibited an excellent safety profile with no serious adverse events. Based on the clinical trials recently published at home and abroad, this article reviews the background, action mechanism, development, and prospect of BAT.
双极雄激素治疗（BAT）是去势抵抗性前列腺癌（CRPC）的新型治疗方法，可显著降低患者血清前列腺特异性抗原（PSA）水平，且具有良好的安全性。笔者结合近期国内外临床试验，对BAT提出的背景、机制、发展进程及前景作一综述。.
Keywords: androgen receptor; castration-resistant prostate cancer; bipolar androgen therapy.